ConductScience.org, home

Paper31346211

Synergy of therapeutic heterologous prime-boost hepatitis B vaccination with CpG-application to improve immune control of persistent HBV infection.

Kosinska AD and 8 others. Sci Rep, 2019. Cited by 32 papers, by iCite.

Cite this record

ConductScience Library. Synergy of therapeutic heterologous prime-boost hepatitis B vaccination with CpG-application to improve immune control of persistent HBV infection. Papers, record 31346211. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/31346211

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Synergy of therapeutic heterologous prime-boost hepatitis B vaccination with CpG-application to improve immune control of persistent HBV infection.
PubMed
Journal
Sci Rep
PubMed
Year
2019
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
32
iCite
Relative citation ratio, by iCite
1.03
iCite
Revised in PubMed
2021-12-04
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Kosinska ADAnna D
2Moeed AAbdul
3Kallin NNina
4Festag JJulia
5Su JJinpeng
6Steiger KKatjahttps://orcid.org/0000-0002-7269-5433
7Michel MLMarie-Louise
8Protzer UUlrikehttps://orcid.org/0000-0002-9421-1911
9Knolle PAPercy A

Source PubMed

Download CSV of authors

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Adjuvants, ImmunologicMajor topic
Hepatitis B VaccinesMajor topic
Hepatitis B, ChronicMajor topic
OligodeoxyribonucleotidesMajor topic
VaccinationMajor topic
Animals
CD4-Positive T-Lymphocytes
CD8-Positive T-Lymphocytes
Cells, Cultured
Female
Hepatitis B Core Antigens
Liver
Male
Mice
Vaccines, DNA
Viral Vaccines

Source PubMed

Download CSV of topics

References32

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
126412123Effective intrahepatic CD8+ T-cell immune responses are induced by low but not high numbers of antigen-expressing hepatocytes.Cell Mol Immunol2016https://conductscience.org/library/papers/26412123PubMed
226292984Mouse Models of Hepatitis B Virus Pathogenesis.Cold Spring Harb Perspect Med2015https://conductscience.org/library/papers/26292984PubMed
38328741Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis.Ann Intern Med1993https://conductscience.org/library/papers/8328741PubMed
428453967Therapeutic vaccination for chronic hepatitis B.Curr Opin Virol2017https://conductscience.org/library/papers/28453967PubMed
529877316Hepatitis B virus infection.Nat Rev Dis Primers2018https://conductscience.org/library/papers/29877316PubMed
626404698Functional classification of memory CD8(+) T cells by CX3CR1 expression.Nat Commun2015https://conductscience.org/library/papers/26404698PubMed
717095599An immunocompetent mouse model for the tolerance of human chronic hepatitis B virus infection.Proc Natl Acad Sci U S A2006https://conductscience.org/library/papers/17095599PubMed
822487943Foxp3+ regulatory T cells protect the liver from immune damage and compromise virus control during acute experimental hepatitis B virus infection in mice.Hepatology2012https://conductscience.org/library/papers/22487943PubMed
923468504Adeno-associated virus-mediated gene transfer leads to persistent hepatitis B virus replication in mice expressing HLA-A2 and HLA-DR1 molecules.J Virol2013https://conductscience.org/library/papers/23468504PubMed
1024412289Hepatic immune regulation and its involvement in viral hepatitis infection.Gastroenterology2014https://conductscience.org/library/papers/24412289PubMed
1112477811CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection.J Virol2003https://conductscience.org/library/papers/12477811PubMed
1226416327Interferon-γ and Tumor Necrosis Factor-α Produced by T Cells Reduce the HBV Persistence Form, cccDNA, Without Cytolysis.Gastroenterology2016https://conductscience.org/library/papers/26416327PubMed
137666518High-level hepatitis B virus replication in transgenic mice.J Virol1995https://conductscience.org/library/papers/7666518PubMed
1424557838Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA.Science2014https://conductscience.org/library/papers/24557838PubMed
1530801899Therapeutic vaccination for chronic hepatitis B: A systematic review and meta-analysis.J Viral Hepat2019https://conductscience.org/library/papers/30801899PubMed
1619500964Heterologous prime-boost vaccination.Curr Opin Immunol2009https://conductscience.org/library/papers/19500964PubMed
1715711573Toll-like receptor 3 promotes cross-priming to virus-infected cells.Nature2005https://conductscience.org/library/papers/15711573PubMed
1830524897Induction of liver-specific intrahepatic myeloid cells aggregation expands CD8 T cell and inhibits growth of murine hepatoma.Oncoimmunology2018https://conductscience.org/library/papers/30524897PubMed
1919302037The liver as a lymphoid organ.Annu Rev Immunol2009https://conductscience.org/library/papers/19302037PubMed
2025673700Inflammatory monocytes recruited to the liver within 24 hours after virus-induced inflammation resemble Kupffer cells but are functionally distinct.J Virol2015https://conductscience.org/library/papers/25673700PubMed

See all 32 referencesDownload CSV of references

Cited by20

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 32 citations.

PMIDTitleJournalYearIn PapersSource
41909658Therapeutic hepatitis B vaccine employing DNA prime - MVA boost scheme requires additional priming with recombinant HBsAg to elicit an adequate antibody response.Front Immunol2026https://conductscience.org/library/papers/41909658PubMed
41893803Protein Priming Followed by a Replication-Competent VSV-GP Vector Boost Induces Sustained Immune Control in Therapeutic Hepatitis B Vaccination.Vaccines (Basel)2026https://conductscience.org/library/papers/41893803PubMed
40799509MVA-HBVac-A novel vaccine vector that allows pan-genotypic targeting of hepatitis B virus by therapeutic vaccination.Mol Ther Nucleic Acids2025https://conductscience.org/library/papers/40799509PubMed
40382583Next-generation immunotherapeutic approaches for blood cancers: Exploring the efficacy of CAR-T and cancer vaccines.Exp Hematol Oncol2025https://conductscience.org/library/papers/40382583PubMed
38987588A liver immune rheostat regulates CD8 T cell immunity in chronic HBV infection.Nature2024https://conductscience.org/library/papers/38987588PubMed
38425450Introducing adjuvant-loaded particulate hepatitis B core antigen as an alternative therapeutic hepatitis B vaccine component.JHEP Rep2024https://conductscience.org/library/papers/38425450PubMed
36985174Dynamics of Hepatitis B Virus Covalently Closed Circular DNA: A Mini-Review.Microorganisms2023https://conductscience.org/library/papers/36985174PubMed
36851121Evaluation of the Effect of CD70 Co-Expression on CD8 T Cell Response in Protein-Prime MVA-Boost Vaccination in Mice.Vaccines (Basel)2023https://conductscience.org/library/papers/36851121PubMed
36714793Efficient stabilization of therapeutic hepatitis B vaccine components by amino-acid formulation maintains its potential to break immune tolerance.JHEP Rep2023https://conductscience.org/library/papers/36714793PubMed
36405686Activation of distinct antiviral T-cell immunity: A comparison of bi- and trispecific T-cell engager antibodies with a chimeric antigen receptor targeting HBV envelope proteins.Front Immunol2022https://conductscience.org/library/papers/36405686PubMed
36203595HBV immune tolerance of HBs-transgenic mice observed through parabiosis with WT mice.Front Immunol2022https://conductscience.org/library/papers/36203595PubMed
35229055Revival of the heterologous prime-boost technique in COVID-19: An outlook from the history of outbreaks.Health Sci Rep2022https://conductscience.org/library/papers/35229055PubMed
35059620Humoral immunity in hepatitis B virus infection: Rehabilitating the B in HBV.JHEP Rep2022https://conductscience.org/library/papers/35059620PubMed
34835264Improving Therapeutic Vaccination against Hepatitis B-Insights from Preclinical Models of Immune Therapy against Persistent Hepatitis B Virus Infection.Vaccines (Basel)2021https://conductscience.org/library/papers/34835264PubMed
34451966Immunogenicity and Antiviral Response of Therapeutic Hepatitis B Vaccination in a Mouse Model of HBeAg-Negative, Persistent HBV Infection.Vaccines (Basel)2021https://conductscience.org/library/papers/34451966PubMed
33992859Innate immunity and HBV persistence.Curr Opin Virol2021https://conductscience.org/library/papers/33992859PubMed
33489122Designing the next-generation therapeutic vaccines to cure chronic hepatitis B: focus on antigen presentation, vaccine properties and effect measures.Clin Transl Immunology2021https://conductscience.org/library/papers/33489122PubMed
32466788HBV X protein-based therapeutic vaccine accelerates viral antigen clearance by mobilizing monocyte infiltration into the liver in HBV carrier mice.J Biomed Sci2020https://conductscience.org/library/papers/32466788PubMed
32131853A novel TLR7 agonist as adjuvant to stimulate high quality HBsAg-specific immune responses in an HBV mouse model.J Transl Med2020https://conductscience.org/library/papers/32131853PubMed
31809638Designing a therapeutic hepatitis B vaccine to circumvent immune tolerance.Hum Vaccin Immunother2020https://conductscience.org/library/papers/31809638PubMed

Download CSV of cited by

Genes13

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/31346211

GET https://conductscience.org/api/papers/v1/31346211/references?page=2